Alessandro Guida

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Alessandro Guida is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

22 Article

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
Cantini, L., Mentrasti, G., Russo, G. L., Signorelli, D., Pasello, G., Rijavec, E., Russano, M., Antonuzzo, L., Rocco, D., Giusti, R., Adamo, V., Genova, C., Tuzi, A., Morabito, A., Gori, S., Verde, N. L., Chiari, R., Cortellini, A., Cognigni, V., Pecci, F. & 30 others, Indini, A., De Toma, A., Zattarin, E., Oresti, S., Pizzutilo, E. G., Frega, S., Erbetta, E., Galletti, A., Citarella, F., Fancelli, S., Caliman, E., Della Gravara, L., Malapelle, U., Filetti, M., Piras, M., Toscano, G., Zullo, L., De Tursi, M., Di Marino, P., D'Emilio, V., Cona, M. S., Guida, A., Caglio, A., Salerno, F., Spinelli, G., Russo, A., Dellepiane, C., Sforza, V., Inno, A. & Migliore, A., Apr 2022, In: ESMO Open. 7, 2, 100406.
Research output: Contribution to journal › Article › peer-review

Open Access
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
Cortellini, A., Giusti, R., Filetti, M., Citarella, F., Adamo, V., Santini, D., Buti, S., Nigro, O., Cantini, L., Di Maio, M., Aerts, J. G. J. V., Bria, E., Bertolini, F., Ferrara, M. G., Ghidini, M., Grossi, F., Guida, A., Berardi, R., Morabito, A., Genova, C. & 29 others, Mazzoni, F., Antonuzzo, L., Gelibter, A., Marchetti, P., Chiari, R., Macerelli, M., Rastelli, F., Della Gravara, L., Gori, S., Tuzi, A., De Tursi, M., Di Marino, P., Mansueto, G., Pecci, F., Zoratto, F., Ricciardi, S., Migliorino, M. R., Passiglia, F., Metro, G., Spinelli, G. P., Banna, G. L., Friedlaender, A., Addeo, A., Ficorella, C., Porzio, G., Tiseo, M., Russano, M., Russo, A. & Pinato, D. J., 2022, In: Journal of Hematology and Oncology. 15, 1, 9.
Research output: Contribution to journal › Article › peer-review
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Cortellini, A., Cannita, K., Tiseo, M., Cortinovis, D. L., Aerts, J. G. J. V., Baldessari, C., Giusti, R., Ferrara, M. G., D'Argento, E., Grossi, F., Guida, A., Berardi, R., Morabito, A., Genova, C., Antonuzzo, L., Mazzoni, F., De Toma, A., Signorelli, D., Gelibter, A., Targato, G. & 32 others, Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Mansueto, G., Zoratto, F., Filetti, M., Bracarda, S., Citarella, F., Marco, R., Cantini, L., Nigro, O., Buti, S., Minuti, G., Landi, L., Ricciardi, S., Migliorino, M. R., Natalizio, S., Simona, C., De Filippis, M., Metro, G., Adamo, V., Russo, A., Spinelli, G. P., Di Maio, M., Banna, G. L., Friedlaender, A., Addeo, A., Pinato, D. J., Ficorella, C. & Porzio, G., 2021, In: European Journal of Cancer. 148, p. 24-35 12 p.
Research output: Contribution to journal › Article › peer-review
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study: The Lancet Oncology
Pinato, D. J., Tabernero, J., Bower, M., Scotti, L., Patel, M., Colomba, E., Dolly, S., Loizidou, A., Chester, J., Mukherjee, U., Zambelli, A., Dalla Pria, A., Aguilar-Company, J., Ottaviani, D., Chowdhury, A., Merry, E., Salazar, R., Bertuzzi, A., Brunet, J., Lambertini, M. & 100 others, Tagliamento, M., Pous, A., Sita-Lumsden, A., Srikandarajah, K., Colomba, J., Pommeret, F., Seguí, E., Generali, D., Grisanti, S., Pedrazzoli, P., Rizzo, G., Libertini, M., Moss, C., Evans, J. S., Russell, B., Harbeck, N., Vincenzi, B., Biello, F., Bertulli, R., Liñan, R., Rossi, S., Carmona-García, M. C., Tondini, C., Fox, L., Baggi, A., Fotia, V., Parisi, A., Porzio, G., Saponara, M., Cruz, C. A., García-Illescas, D., Felip, E., Roqué Lloveras, A., Sharkey, R., Roldán, E., Reyes, R., Earnshaw, I., Ferrante, D., Marco-Hernández, J., Ruiz-Camps, I., Gaidano, G., Patriarca, A., Bruna, R., Sureda, A., Martinez-Vila, C., Sanchez de Torre, A., Cantini, L., Filetti, M., Rimassa, L., Chiudinelli, L., Franchi, M., Krengli, M., Santoro, A., Prat, A., Van Hemelrijck, M., Diamantis, N., Newsom-Davis, T., Gennari, A., Cortellini, A., Swallow, J., Chung, C., Dettorre, G., Chopra, N., Lee, A. J., Sng, C. C., Wong, Y. N. S., Galazi, M., Benafif, S., Dileo, P., Patel, G., Wu, A., Sinclair, A., Soosaipillai, G., Jones, E., Jackson, A., Piccart, M., Colomba-Blameble, E., Segui, E., Garcia Illescas, D., Mirallas, O., Carbó, A., Garcia, I., Wuerstlein, R., Mesia, R., Maluquer, C., D'Avanzo, F., Tonini, G., Provenzano, S., Tovazzi, V., Ficorella, C., Queirolo, P., Giusti, R., Mazzoni, F., Zoratto, F., Tucci, M., Berardi, R., Guida, A., Bracarda, S., Iglesias, M. & group, O. S., 2021, In: Lancet Oncol.. 22, 12, p. 1669-1680 12 p.
Research output: Contribution to journal › Article › peer-review
Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer
Gregorc, V., Mazzarella, L., Lazzari, C., Graziano, P., Vigneri, P., Genova, C., Toschi, L., Ciliberto, G., Bonanno, L., Delmonte, A., Bucci, G., Rossi, A., Motta, G., Coco, S., Marinello, A., Buglioni, S., Cangi, M. G., Di Micco, C., Bandiera, A., Bonfiglio, S. & 6 others, Pecciarini, L., Guida, A., Ceol, A., Frige', G., De Maria, R. & Pelicci, P. G., Jul 2021, In: Clin. Lung Cancer. 22, 4, p. e637-e641
Research output: Contribution to journal › Article › peer-review

Alessandro Guida

Fingerprint

Network

Dive into details

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study: The Lancet Oncology

Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer

Alessandro Guida

Fingerprint

Network

Research output

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study: The Lancet Oncology

Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer